Article Figures & Data
Figures
- Figure 1.
Study design. A: Study protocol timeline; a baseline FDG-PET/CT was performed 0-2 weeks before start of pazopanib therapy. B: study profile.
- Figure 2.
FDG-response monitoring.
- Figure 3.
FDG-PET response compared to clinical outcome. All patients who showed any degree of increase in metabolic activity (n=10, 0.25% - 46.47%) at two weeks, excluding the two who stopped prematurely due to toxicity, were radiologically confirmed as non-responders after eight weeks of therapy.
- Figure 4.
Geometric mean of the ΔSUL per metastatic site at FDG-PET at two weeks versus baseline. Of the eight patients with bone lesions five were non-responders, one patient responded to pazopanib treatment, and two patients discontinued pazopanib prematurely due to toxicity.
- Figure 5.
Association between pazopanib pharmacokinetics and response at eight weeks.
Tables
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.